甲状腺眼病的生物制剂治疗专家共识  

Expert Consensus on the Treatment of Thyroid Eye Disease with Biologic Agents

作　　者：北京医院国家老年医学中心 中国医药教育协会老年药学专业委员会 金鹏飞[2] 赵紫楠[2] 高洪伟[3] 石璐[4] Beijing Hospital,National Center of Gerontology;Geriatric Pharmacy Professional Committee of the Chinese Pharmaceutical Education Association

机构地区：[1]不详 [2]北京医院 [3]北京大学第三医院 [4]南昌大学第二附属医院

出　　处：《临床药物治疗杂志》2025年第3期1-10,共10页Clinical Medication Journal

摘　　要：由北京医院国家老年医学中心、中国医药教育协会老年药学专业委员会牵头多学科专家团队制订了《甲状腺眼病的生物制剂治疗专家共识》。该共识系统整合了国内外最新循证证据及临床实践经验,聚焦替妥尤单抗、托珠单抗、利妥昔单抗等生物制剂的适应证选择、治疗策略、疗效评估及安全性管理等核心问题,最终形成14条推荐意见,明确了生物制剂在中重度活动期甲状腺眼病(TED)、糖皮质激素抵抗患者及其他特殊人群中的应用原则,并针对高血糖、听力损伤等不良反应提出了监测与处理方案。该共识旨在为临床医师和药师提供科学、实用的治疗指导,推动TED诊疗的同质化与精准化,最终改善患者预后及生活质量。The Expert Consensus on Biological Agents for Thyroid Eye Disease(TED),developed by a multidisciplinary expert team led by the National Center for Gerontology at Beijing Hospital and the Geriatric Pharmacy Committee of the China Medicine Education Association,systematically integrates the latest global evidence and clinical experience.It focuses on core issues such as indication selection,treatment strategies,efficacy evaluation,and safety management of biological agents including teprotumumab,tocilizumab,and rituximab,culminating in 14 evidence-based recommendations.The consensus clarifies the principles for applying biologics in patients with moderate-to-severe active TED,glucocorticoid-resistant cases,and other special populations,while proposing monitoring and management strategies for adverse reactions such as hyperglycemia and hearing impairment.Aimed at providing clinicians and pharmacists with scientific and practical guidance,this consensus seeks to advance the standardization and precision of TED diagnosis and treatment,ultimately improving patient prognosis and quality of life.

关 键 词：共识 甲状腺眼病 生物制剂 药物治疗管理 

分 类 号：R977[医药卫生—药品] R581[医药卫生—药学] R771.3